BDSX logo

BDSX
Biodesix Inc

1,635
Mkt Cap
$150.92M
Volume
30,179.00
52W High
$20.21
52W Low
$5.00
PE Ratio
-3.71
BDSX Fundamentals
Price
$14.93
Prev Close
$15.18
Open
$15.04
50D MA
$13.94
Beta
0.53
Avg. Volume
57,979.91
EPS (Annual)
-$4.67
P/B
16.52
Rev/Employee
$264,967.07
$105.11
Loading...
Loading...
News
all
press releases
Can MDT Stock Gain From Its Planned Acquisition of SPR Therapeutics?
Medtronic eyes a $650 million acquisition of SPR, adding the FDA-cleared SPRINT PNS System to expand its chronic pain treatment offerings ahead of the fiscal 2027 closing.
News Placeholder
More News
News Placeholder
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.
News Placeholder
MMED's Latest Study Supports the Strength of 780G SmartGuard Algorithm
MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.
News Placeholder
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
QGEN's new QIA Agent platform uses conversational AI to streamline experiment planning and ordering support.
News Placeholder
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL's strong Q1 earnings, digital growth and expanding high-tech platform support long-term upside despite rising cost pressures.
News Placeholder
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST's HVP business and GLP-1 demand are driving growth, but can Annex 1 tailwinds and margin gains offset inflation and SmartDose risks?
News Placeholder
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now
Cardinal Health's specialty growth, strong cash flow and expanding higher-margin businesses are boosting earnings momentum despite IRA and GMPD risks.
News Placeholder
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
News Placeholder
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
News Placeholder
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price
Canaccord Genuity Group increased their price objective on shares of Biodesix from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available